Cerevel Therapeutics Holdings(US:CERE)2023-11-01 14:54Financial Status - Cerevel had $758 million in cash, cash equivalents, and marketable securities as of September 30, 2023[9] - Cerevel raised $499 million net proceeds from a public offering of common stock in October 2023[3] - Cerevel expects its cash resources to support operations into 2026 due to disciplined spending[11] Pipeline Progress - Tavapadon - Phase 3 TEMPO-3 trial data for adjunctive therapy in Parkinson's is expected in the first half of 2024[23] - Phase 3 TEMPO-1 and TEMPO-2 trial data for monotherapy in Parkinson's is expected in the second half of 2024[23] - In a Phase 2 trial, Tavapadon demonstrated a 4.8 point improvement vs placebo at week 15 (p=0.04) when measuring MDS-UPDRS III[62] - In the same Phase 2 trial, Tavapadon demonstrated a 5.8-point improvement over placebo at week 15 (p=0.02) when measuring MDS-UPDRS Part II + III[62] Pipeline Progress - Emraclidine - Data from two Phase 2 EMPOWER trials in schizophrenia is expected in the second half of 2024[7] - A Phase 1 healthy elderly volunteer trial to support development in Alzheimer's disease psychosis (ADP) is ongoing[21] Pipeline Progress - Darigabat - Data from the Phase 2 REALIZE trial in focal epilepsy is expected mid-year 2024[8] - The Phase 2 ADAPT trial in panic disorder is ongoing[8] - Darigabat 7.5 mg BID showed a 3.9-point improvement versus placebo (p=0.036), and Darigabat 25 mg BID showed a 4.5-point improvement versus placebo (p=0.008) in a Phase 1 acute anxiety trial[66]